Research Analysts Set Expectations for CRL FY2027 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Research analysts at Zacks Research issued their FY2027 EPS estimates for Charles River Laboratories International in a report issued on Wednesday, March 12th. Zacks Research analyst R. Department forecasts that the medical research company will post earnings of $11.39 per share for the year. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the business earned $2.46 earnings per share. The firm's quarterly revenue was down 1.1% compared to the same quarter last year.

Several other research firms have also issued reports on CRL. CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. Morgan Stanley cut their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Barclays cut their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 18th. The Goldman Sachs Group cut their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of "Hold" and an average price target of $198.36.

Remove Ads

Charles River Laboratories International Price Performance

NYSE:CRL traded up $2.01 during midday trading on Friday, hitting $177.02. The company had a trading volume of 1,011,923 shares, compared to its average volume of 711,526. Charles River Laboratories International has a 52-week low of $150.79 and a 52-week high of $274.77. The stock's fifty day moving average price is $167.46 and its 200-day moving average price is $184.33. The company has a market capitalization of $9.05 billion, a PE ratio of 1,180.13, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently bought and sold shares of CRL. Wellington Management Group LLP raised its stake in Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after buying an additional 3,738,018 shares in the last quarter. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International in the fourth quarter worth about $172,752,000. Norges Bank bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $98,886,000. Nomura Holdings Inc. bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,820,000. Finally, Raymond James Financial Inc. bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $42,776,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).